Bevacizumab plus cisplatin vs. cisplatin alone for fluid buildup from cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding bevacizumab (a drug that blocks blood vessel growth) to cisplatin (a standard chemotherapy) is better than cisplatin alone for controlling fluid buildup caused by adenocarcinoma. If you have not had prior treatment for this fluid, you may qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have fluid buildup in your chest or belly from a type of cancer called adenocarcinoma (and no known gene mutations).
- You have not had any previous treatment for this fluid buildup.
- You are still able to get up and take care of yourself for at least half the day (ECOG score 2 or less).
- Your doctor expects you to live longer than 3 months.
- Your blood counts, kidney, and liver function are within certain limits (the study team will check these).
- You do not have uncontrolled high blood pressure, recent bleeding problems, serious heart or lung issues, or active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
This trial tests whether adding a traditional Chinese medicine called Xuan Yin Ning to an existing drug (bevacizumab) can help control fluid buildup around the lung in people with advanced non-small cell lung cancer. The goal is to reduce symptoms like shortness of breath and improve quality of life.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This trial tests a new immunotherapy medicine (adebrelimab) added to standard care for people with pancreatic cancer that has caused fluid buildup in the belly or around the lungs. The goal is to see if this combination can help control the cancer and reduce the fluid buildup.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
Hear when a new Overall Response Rate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.